Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab vs Ranibizumab in AMD (AxL-2009)
NCT01014468Phase 3Unknown
- Sponsor
- Instituto de Olhos de Goiânia
- Start
- Mar 2009
- Primary completion
- Nov 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of bevacizumab and ranibizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Instituto de Olhos de Goiânia. Primary endpoints: Vision change at 6 months, Anatomical changes at 6 months and 1 more. Status: unknown.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01014468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014468.